Together, these data suggest that HDAC inhibition rather than PI3K/AKT pathway inhibition associated with fimepinostat therapy is most likely responsible for the observed perturbation of AR and Myc levels in prostate cancer cell lines. Here, AR is linked to Familial prostate cancer.